Gremlin-1 antibody
US10947304B2 · kind B2 · utility
4Cited by
24References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2017 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Dec 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.